Ruxolitinib and Decitabine for High Risk Hematological Malignancies
Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and
Decitabine intensified Conditioning Regimen in Patients with High Risk hematological
malignancies undergoing allogeneic peripheral blood stem cell transplantation.